Titre
First in-human radiation dosimetry of (68)Ga-NODAGA-RGDyK.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Gnesin, S.
Auteure/Auteur
Mitsakis, P.
Auteure/Auteur
Cicone, F.
Auteure/Auteur
Deshayes, E.
Auteure/Auteur
Dunet, V.
Auteure/Auteur
Gallino, A.F.
Auteure/Auteur
Kosinski, M.
Auteure/Auteur
Baechler, S.
Auteure/Auteur
Buchegger, F.
Auteure/Auteur
Viertl, D.
Auteure/Auteur
Prior, J.O.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
2191-219X
Statut éditorial
Publié
Date de publication
2017-12
Volume
7
Numéro
1
Première page
43
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Integrin-targeting radiopharmaceuticals have potential broad applications, spanning from cancer theranostics to cardiovascular diseases. We have previously reported preclinical dosimetry results of (68)Ga-NODAGA-RGDyK in mice. This study presents the first human dosimetry of (68)Ga-NODAGA-RGDyK in the five consecutive patients included in a clinical imaging protocol of carotid atherosclerotic plaques. Five male patients underwent whole-body time-of-flight (TOF) PET/CT scans 10, 60 and 120 min after tracer injection (200 MBq). Quantification of (68)Ga activity concentration was first validated by a phantom study. To be used as input in OLINDA/EXM, time-activity curves were derived from manually drawn regions of interest over the following organs: brain, thyroid, lungs, heart, liver, spleen, stomach, kidneys, red marrow, pancreas, small intestine, colon, urinary bladder and whole body. A separate dosimetric analysis was performed for the choroid plexuses. Female dosimetry was extrapolated from male data. Effective doses (EDs) were estimated according to both ICRP60 and ICRP103 assuming 30-min and 1-h voiding cycles.
The body regions receiving the highest dose were urinary bladder, kidneys and choroid plexuses. For a 30-min voiding cycle, the EDs were 15.7 and 16.5 μSv/MBq according to ICRP60 and ICRP103, respectively. The extrapolation to female dosimetry resulted in organ absorbed doses 17% higher than those of male patients, on average. The 1-h voiding cycle extrapolation resulted in EDs of 19.3 and 19.8 μSv/MBq according to ICRP60 and ICRP103, respectively. A comparison is made with previous mouse dosimetry and with other human studies employing different RGD-based radiopharmaceuticals.
According to ICRP60/ICRP103 recommendations, an injection of 200 MBq (68)Ga-NODAGA-RGDyK leads to an ED in man of 3.86/3.92 mSv. For future therapeutic applications, specific attention should be directed to delivered dose to kidneys and potentially also to the choroid plexuses.
Clinical trial.gov, NCT01608516.
The body regions receiving the highest dose were urinary bladder, kidneys and choroid plexuses. For a 30-min voiding cycle, the EDs were 15.7 and 16.5 μSv/MBq according to ICRP60 and ICRP103, respectively. The extrapolation to female dosimetry resulted in organ absorbed doses 17% higher than those of male patients, on average. The 1-h voiding cycle extrapolation resulted in EDs of 19.3 and 19.8 μSv/MBq according to ICRP60 and ICRP103, respectively. A comparison is made with previous mouse dosimetry and with other human studies employing different RGD-based radiopharmaceuticals.
According to ICRP60/ICRP103 recommendations, an injection of 200 MBq (68)Ga-NODAGA-RGDyK leads to an ED in man of 3.86/3.92 mSv. For future therapeutic applications, specific attention should be directed to delivered dose to kidneys and potentially also to the choroid plexuses.
Clinical trial.gov, NCT01608516.
PID Serval
serval:BIB_B7AEC05B72D8
PMID
Open Access
Oui
Date de création
2017-05-24T09:09:32.216Z
Date de création dans IRIS
2025-05-20T23:18:49Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
13550_2017_Article_288.pdf
Version du manuscrit
published
Taille
1.57 MB
Format
Adobe PDF
PID Serval
serval:BIB_B7AEC05B72D8.P001
URN
urn:nbn:ch:serval-BIB_B7AEC05B72D84
Somme de contrôle
(MD5):d985fa3f8d8f25f39267d148a38d95b6